I want to thank ACIP for their thoughtful discussion and scientific deliberation on the current data which informed my recommendation.Important for Mac users! If you have personal files, e.g.
While today’s action was an initial step related to booster shots, it will not distract from our most important focus of primary vaccination in the United States and around the world. We will address, with the same sense of urgency, recommendations for the Moderna and J&J vaccines as soon as those data are available. Today, ACIP only reviewed data for the Pfizer-BioNTech vaccine. This aligns with the FDA’s booster authorization and makes these groups eligible for a booster shot. I believe we can best serve the nation’s public health needs by providing booster doses for the elderly, those in long-term care facilities, people with underlying medical conditions, and for adults at high risk of disease from occupational and institutional exposures to COVID-19. In a pandemic, even with uncertainty, we must take actions that we anticipate will do the greatest good. At CDC, we are tasked with analyzing complex, often imperfect data to make concrete recommendations that optimize health. The following is attributable to Dr. Walensky:Īs CDC Director, it is my job to recognize where our actions can have the greatest impact. We will also evaluate with similar urgency available data in the coming weeks to swiftly make additional recommendations for other populations or people who got the Moderna or Johnson & Johnson vaccines. With the Delta variant’s dominance as the circulating strain and cases of COVID-19 increasing significantly across the United States, a booster shot will help strengthen protection against severe disease in those populations who are at high-risk for exposure to COVID-19 or the complications from severe disease.ĬDC will continue to monitor the safety and effectiveness of COVID-19 vaccines to ensure appropriate recommendations to keep all Americans safe. Many of the people who are now eligible to receive a booster shot received their initial vaccine early in the vaccination program and will benefit from additional protection. people aged 18-64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks.people aged 18–49 years with underlying medical conditions may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks, and.
0 kommentar(er)
